Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26316428 | 0.92 | TSHR (0.40) | TSHROPRM1CHRM1AKR1A1CHRM3 | |
| SCHEMBL18765448 | 0.83 | TSHR (0.35) | TSHR | |
| SCHEMBL22345154 | 0.83 | METAP1 (0.36) | TSHR | |
| SCHEMBL18520646 | 0.81 | OPRM1 (0.38) | TSHROPRM1 | |
| SCHEMBL20791965 | 0.81 | OPRM1 (0.38) | TSHROPRM1 | |
| SCHEMBL23207686 | 0.81 | TSHR (0.33) | TSHR | |
| SCHEMBL17607461 | 0.81 | TSHR (0.33) | TSHR | |
| SCHEMBL18790926 | 0.81 | TSHR (0.33) | TSHR | |
| SCHEMBL13674199 | 0.81 | TSHR (0.39) | TSHRCHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL4654330 | 0.79 | DNM1 (0.43) | TSHROPRM1TDP1CYP3A4FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014108487-A1 | P-STEREOGENIC CHIRAL PRECURSOR OF CHIRAL LIGANDS AND USE THEREOF | UNIVERSITE D'AIX-MARSEILLE (FR) | 2014-07-17 | — | — | WO | claimed |
| WO-2023009952-A1 | SOLVENTS, METHODS, AND SYSTEMS FOR ISOLATING CANNABINOIDS FROM PLANTS EXTRACTS OR FROM SYNTHETIC PATHWAYS | NOEL ARMAND J (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023009956-A1 | PROCESSES FOR CONVERTING CANNABINOIDS INTO CANNABINOID DERIVATIVES AND RECOVERING THE SAME | NOEL ARMAND J (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023009954-A1 | SOLVENTS, METHODS, AND SYSTEMS FOR ISOLATING BOTANICAL EXTRACTS FROM PLANTS | NOEL ARMAND J (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023009955-A1 | PROCESSES AND SYSTEMS FOR CONVERTING CANNABINOIDS INTO CANNABINOID DERIVATIVES AND ISOLATING THE SAME | NOEL ARMAND J (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20200171214-A1 | BIORESORBABLE SURFACE COATING FOR DELAYING DEGRADATION | DREI LILIEN PVG GMBH & CO. KG (DE) | 2020-06-04 | — | — | US | disclosed |
| EP-3648806-A1 | BIORESORBABLE SURFACE COATING FOR DELAYING DEGRADATION | Drei Lilien PVG GmbH & Co. KG (DE) | 2020-05-13 | — | — | EP | disclosed |
| US-10403821-B2 | Method of making an electrode | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| WO-2019008192-A1 | BIORESORBABLE SURFACE COATING FOR DELAYING DEGRADATION | DREI LILIEN PVG GMBH & CO. KG (DE) | 2019-01-10 | — | — | WO | disclosed |
| US-20170194566-A1 | METHOD OF MAKING AN ELECTRODE | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-1569652-A2 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | Pharmasset Ltd. (BB) | 2005-09-07 | — | — | EP | disclosed |
| US-6908924-B2 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | PHARMASSET, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| CN-1620295-A | Preparation of intermediates for the synthesis of antiviral nucleosides | PHARMASSET LTD (BB) | 2005-05-25 | — | — | CN | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | TSHR 4374/4885OPRM1 3519/4885CHRM1 2358/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | TSHR 4420/4885OPRM1 3130/4885CHRM1 3494/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | TSHR 3766/4885OPRM1 1998/4885CHRM1 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.